Rigel Pharmaceuticals | RIGL - Les Intérêts Débiteurs Sur La Dette





Les Intérêts Débiteurs Sur La Dette Changement Date
Agenus USD 14.67M 1.35M 2026-03
Amgen USD 653M 94.99B 2026-09
Anika Therapeutics 183.47M 4.09M 2026-06
Arrowhead Research USD 24.56M 716K 2026-06
AstraZeneca USD 371M 31M 2026-09
BioMarin Pharmaceutical USD 55.63M 7.67M 2026-09
Bristol-Myers Squibb USD 403M 4M 2026-09
Daiichi Sankyo JPY 14.13B 10.56B 2026-09
Eli Lilly USD 316M 201.3M 2026-09
Halozyme Therapeutics USD 6.04M 457K 2026-09
Heron Therapeutics USD 600K 100K 2024-12
Intrexon USD 2K 5K 2024-06
Ionis Pharmaceuticals USD 18M 1000K 2026-06
Karyopharm Therapeutics USD 12.55M 66K 2026-03
Ligand Pharmaceuticals USD 1.78M 875K 2025-12
MacroGenics USD 4.4M 493K 2026-06
Neurocrine Biosciences USD 300K 2.6M 2026-09
Pfizer USD 662M 5M 2026-09
Regeneron Pharmaceuticals USD 11M 1.9M 2026-06
Rigel Pharmaceuticals USD 2.06M 31K 2024-09
Sangamo BioSciences 97.56M 11.39M 2025-06
Ultragenyx Pharmaceutical USD 20M 2M 2026-09
Veracyte USD 2K 1000 2023-12